Track topics on Twitter Track topics that are important to you
Kura Oncology is preparing to launch an early-stage study next quarter for its experimental candidate KO-539 as a treatment f -More-
Precision cancer medicine company Kura Oncology Inc. netted $94.3mm through a public offering of 5.9mm common shares at $17. Proceeds are earmarked for continued R&D including development of tipifarni...
Precision cancer medicine company Kura Oncology Inc. netted $108.4mm through a public offering of 6.8mm common shares (including the overallotment) at $17. Proceeds are earmarked for continued R&D inc...
$KURA Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539 https://globenewswire.com/news-release/2019/03/05/1747923/0/en/Kura-Oncology-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-Menin-MLL
$KURA Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539 https://globenewswire.com/news-release/2019/03/05/1747923/0/en/Kura-Oncology-Announces-FDA-Cleara...
We studied 4 Ma old isolated pharyngeal teeth from lake sediments of Çevirme (Tekman Palaeolake, Erzurum Province). Based on shape characters defined for 3D models of modern species, we found that th...
Kura MD was founded in 2013 by Kevin Hamm, a successful serial entrepreneur and long-time healthcare insurance executive to develop the next generation of telehealth solutions. Th...
We have published hundreds of Kura MD Inc. news stories on BioPortfolio along with dozens of Kura MD Inc. Clinical Trials and PubMed Articles about Kura MD Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kura MD Inc. Companies in our database. You can also find out about relevant Kura MD Inc. Drugs and Medications on this site too.